Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 5.50
UTHR's Cash to Debt is ranked higher than
66% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. UTHR: 5.50 )
UTHR' s 10-Year Cash to Debt Range
Min: 0.91   Max: 5455.83
Current: 5.5

0.91
5455.83
Equity to Asset 0.66
UTHR's Equity to Asset is ranked higher than
73% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. UTHR: 0.66 )
UTHR' s 10-Year Equity to Asset Range
Min: 0.43   Max: 0.94
Current: 0.66

0.43
0.94
Interest Coverage 30.63
UTHR's Interest Coverage is ranked higher than
55% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 30.63 )
UTHR' s 10-Year Interest Coverage Range
Min: 2.02   Max: 3302.25
Current: 30.63

2.02
3302.25
F-Score: 8
Z-Score: 10.27
M-Score: -2.33
WACC vs ROIC
11.75%
43.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 41.82
UTHR's Operating margin (%) is ranked higher than
97% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. UTHR: 41.82 )
UTHR' s 10-Year Operating margin (%) Range
Min: -24714.81   Max: 46.03
Current: 41.82

-24714.81
46.03
Net-margin (%) 26.39
UTHR's Net-margin (%) is ranked higher than
95% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. UTHR: 26.39 )
UTHR' s 10-Year Net-margin (%) Range
Min: -23703.7   Max: 56.09
Current: 26.39

-23703.7
56.09
ROE (%) 27.55
UTHR's ROE (%) is ranked higher than
97% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. UTHR: 27.55 )
UTHR' s 10-Year ROE (%) Range
Min: -95.31   Max: 30.84
Current: 27.55

-95.31
30.84
ROA (%) 16.82
UTHR's ROA (%) is ranked higher than
97% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. UTHR: 16.82 )
UTHR' s 10-Year ROA (%) Range
Min: -85.24   Max: 26.08
Current: 16.82

-85.24
26.08
ROC (Joel Greenblatt) (%) 112.50
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. UTHR: 112.50 )
UTHR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1861.26   Max: 114.23
Current: 112.5

-1861.26
114.23
Revenue Growth (3Y)(%) 23.90
UTHR's Revenue Growth (3Y)(%) is ranked higher than
90% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. UTHR: 23.90 )
UTHR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 231.7
Current: 23.9

0
231.7
EBITDA Growth (3Y)(%) 22.80
UTHR's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. UTHR: 22.80 )
UTHR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56   Max: 127.7
Current: 22.8

-56
127.7
EPS Growth (3Y)(%) 19.70
UTHR's EPS Growth (3Y)(%) is ranked higher than
89% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. UTHR: 19.70 )
UTHR' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4   Max: 153.6
Current: 19.7

-50.4
153.6
» UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

UTHR Guru Trades in Q1 2014

Paul Tudor Jones 9,167 sh (+79.75%)
Joel Greenblatt 316,489 sh (+62.64%)
Jim Simons 287,940 sh (+28.39%)
John Hussman 134,000 sh (unchged)
Steven Cohen 2,497 sh (-89.67%)
» More
Q2 2014

UTHR Guru Trades in Q2 2014

Joel Greenblatt 646,066 sh (+104.14%)
John Hussman 134,000 sh (unchged)
Paul Tudor Jones 8,168 sh (-10.90%)
Jim Simons 252,478 sh (-12.32%)
» More
Q3 2014

UTHR Guru Trades in Q3 2014

Jean-Marie Eveillard 262,080 sh (New)
Steven Cohen 8,700 sh (New)
Joel Greenblatt 288,401 sh (-55.36%)
John Hussman 50,000 sh (-62.69%)
Paul Tudor Jones 3,019 sh (-63.04%)
Jim Simons 2,378 sh (-99.06%)
» More
Q4 2014

UTHR Guru Trades in Q4 2014

Jim Simons 185,238 sh (+7689.66%)
Jean-Marie Eveillard 360,180 sh (+37.43%)
Joel Greenblatt 323,088 sh (+12.03%)
John Hussman 50,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones 2,400 sh (-20.50%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.40
UTHR's P/E(ttm) is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 28.40 )
UTHR' s 10-Year P/E(ttm) Range
Min: 8.83   Max: 218.78
Current: 28.4

8.83
218.78
Forward P/E 11.14
UTHR's Forward P/E is ranked higher than
98% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 11.14 )
N/A
PE(NRI) 28.00
UTHR's PE(NRI) is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 28.00 )
UTHR' s 10-Year PE(NRI) Range
Min: 8.84   Max: 227.53
Current: 28

8.84
227.53
P/B 6.60
UTHR's P/B is ranked higher than
66% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. UTHR: 6.60 )
UTHR' s 10-Year P/B Range
Min: 2.01   Max: 10.39
Current: 6.6

2.01
10.39
P/S 7.40
UTHR's P/S is ranked higher than
82% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. UTHR: 7.40 )
UTHR' s 10-Year P/S Range
Min: 2.83   Max: 18.02
Current: 7.4

2.83
18.02
PFCF 28.50
UTHR's PFCF is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 28.50 )
UTHR' s 10-Year PFCF Range
Min: 9.7   Max: 666.33
Current: 28.5

9.7
666.33
POCF 24.60
UTHR's POCF is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 24.60 )
UTHR' s 10-Year POCF Range
Min: 8.25   Max: 1599.5
Current: 24.6

8.25
1599.5
EV-to-EBIT 13.92
UTHR's EV-to-EBIT is ranked higher than
97% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 13.92 )
UTHR' s 10-Year EV-to-EBIT Range
Min: -163.7   Max: 363.2
Current: 13.92

-163.7
363.2
PEG 0.50
UTHR's PEG is ranked higher than
100% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 0.50 )
UTHR' s 10-Year PEG Range
Min: 0.49   Max: 0.76
Current: 0.5

0.49
0.76
Shiller P/E 49.60
UTHR's Shiller P/E is ranked higher than
95% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 49.60 )
UTHR' s 10-Year Shiller P/E Range
Min: 24.86   Max: 129.35
Current: 49.6

24.86
129.35
Current Ratio 1.93
UTHR's Current Ratio is ranked higher than
60% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. UTHR: 1.93 )
UTHR' s 10-Year Current Ratio Range
Min: 0.98   Max: 19.33
Current: 1.93

0.98
19.33
Quick Ratio 1.80
UTHR's Quick Ratio is ranked higher than
61% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. UTHR: 1.80 )
UTHR' s 10-Year Quick Ratio Range
Min: 0.9   Max: 19.08
Current: 1.8

0.9
19.08
Days Inventory 167.07
UTHR's Days Inventory is ranked higher than
84% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 167.07 )
UTHR' s 10-Year Days Inventory Range
Min: 118.32   Max: 518.99
Current: 167.07

118.32
518.99
Days Sales Outstanding 45.97
UTHR's Days Sales Outstanding is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. UTHR: 45.97 )
UTHR' s 10-Year Days Sales Outstanding Range
Min: 36.71   Max: 675.93
Current: 45.97

36.71
675.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 153.00
UTHR's Price/Net Cash is ranked higher than
61% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. UTHR: 153.00 )
UTHR' s 10-Year Price/Net Cash Range
Min: 1.49   Max: 113.59
Current: 153

1.49
113.59
Price/Net Current Asset Value 39.40
UTHR's Price/Net Current Asset Value is ranked higher than
65% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. UTHR: 39.40 )
UTHR' s 10-Year Price/Net Current Asset Value Range
Min: 1.44   Max: 247.14
Current: 39.4

1.44
247.14
Price/Tangible Book 6.80
UTHR's Price/Tangible Book is ranked higher than
72% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. UTHR: 6.80 )
UTHR' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 17.88
Current: 6.8

1.16
17.88
Price/DCF (Projected) 2.20
UTHR's Price/DCF (Projected) is ranked higher than
97% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 2.20 )
UTHR' s 10-Year Price/DCF (Projected) Range
Min: 1.37   Max: 24.34
Current: 2.2

1.37
24.34
Price/Median PS Value 1.00
UTHR's Price/Median PS Value is ranked higher than
86% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. UTHR: 1.00 )
UTHR' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 328.57
Current: 1

0.46
328.57
Price/Peter Lynch Fair Value 1.10
UTHR's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 1.10 )
UTHR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.5   Max: 5.77
Current: 1.1

0.5
5.77
Price/Graham Number 2.70
UTHR's Price/Graham Number is ranked higher than
96% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. UTHR: 2.70 )
UTHR' s 10-Year Price/Graham Number Range
Min: 0.99   Max: 5.79
Current: 2.7

0.99
5.79
Earnings Yield (Greenblatt) 7.10
UTHR's Earnings Yield (Greenblatt) is ranked higher than
97% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. UTHR: 7.10 )
UTHR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 18
Current: 7.1

0.3
18
Forward Rate of Return (Yacktman) 45.13
UTHR's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 15.81 vs. UTHR: 45.13 )
UTHR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.2   Max: 56.9
Current: 45.13

-50.2
56.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UTH.Germany,
United Therapeutics Corp was incorporated in Delaware in June 1996. It is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its key therapeutic products and product candidates include: Prostacyclin Analogues, Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product is Remodulin (treprostinil) Injection (Remodulin), which is administered subcutaneously (under the skin) or intravenously (in the vein) for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Phosphodiesterase Type 5 (PDE-5) Inhibitor. PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cyclic GMP) in cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Monoclonal Antibody (MAb), MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. The Company is developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute (NCI) of the United States National Institutes of Health (NIH). Glycobiology Antiviral Agents, Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a broad range of viruses. Cell-Based Therapy,iIn 2011, the Company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH. Lung Transplantation, the Company is engaged in developing engineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The Company competes with a number of approved products including the following: Flolan, Ventavis, Ilomedin , Tracleer, Revatio, Letairis , Veletri, Adempas, Opsumit , generic epoprostenol and generic sildenafil citrate. The Company's operations must comply with extensive laws and regulations in the United States and other countries, including FDA regulations.
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
FDA Approval Of Cancer Drug Catapults United Therapeutics Shares By 2% Mar 11 2015 
Weekly CFO Sells Highlight: United Therapeutics Corp, Williams Companies Inc, Facebook Inc. Oct 12 2014 
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares Dec 27 2013 
John Hussman's Third Quarter Top 5 Nov 07 2013 
Vanguard Health Care Fund Selling Update Oct 30 2013 
comment on UTHR May 11 2013 
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
5 Fast-Growing Small-Cap Stocks to Watch Mar 26 2013 
comment on UTHR Mar 23 2013 


More From Other Websites
MedImmune, Tech Council of Maryland chart path for region's biotech community Mar 30 2015
Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks... Mar 27 2015
United Therapeutics (UTHR) Crumbles: Stock Falls by 6.5% - Tale of the Tape Mar 26 2015
Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)’s 18% Spike Mar 25 2015
Retrophin Soars on FDA Approval of Bile Acid Disorder Drug - Analyst Blog Mar 19 2015
Akorn, Inc. (AKRX), United Therapeutics Corporation (UTHR) Among Consonance Capital’s Winning Bets... Mar 19 2015
To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher Mar 18 2015
SteadyMed hopes to break Bay Area IPO lull with $68.4M offering this week Mar 17 2015
Watch these drug stocks Monday Mar 13 2015
These new meds could move stocks Mar 13 2015
The Zacks Analyst Blog Highlights: AbbVie, Pharmacyclics, Amgen, United Therapeutics and Regeneron -... Mar 12 2015
United Therapeutics upgraded by Argus Mar 12 2015
United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog Mar 11 2015
United Therapeutics Mar 10 2015
United Therapeutics Wins FDA Nod, Priority Voucher Mar 10 2015
UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure Mar 10 2015
United Therapeutics Receives a Rare Pediatric Disease Priority Review Voucher following the Approval... Mar 10 2015
FDA Approves Unituxin™ (dinutuximab) for the Treatment of Pediatric High-Risk Neuroblastoma Mar 10 2015
FDA approves United Therapeutics' drug for treating cancer in children Mar 10 2015
UNITED THERAPEUTICS CORP Financials Feb 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK